TABLE 2.
Association between the risk group and prevalent clinicopathological parameters.
| Term | High-risk group (n = 83) | Low-risk group (n = 83) | p-value |
|---|---|---|---|
| Age | 60.54 (±13.23) | 58.07 (±13.87) | 0.264 |
| Gender | |||
| Male | 51 (61.45%) | 56 (67.47%) | |
| Female | 32 (38.55%) | 27 (32.53%) | 0.516 |
| IDH status | |||
| Wild type | 77 (92.77%) | 71 (85.54%) | |
| Mutant | 2 (2.41%) | 9 (10.84%) | 0.056 |
| 1p19q co-deletion | |||
| co-del | 0 | 0 | |
| Non-codel | 81 (97.59%) | 79 (95.18%) | NA |
| MGMTp methylation | |||
| Methylated | 22 (26.51%) | 33 (39.76%) | |
| Unmethylated | 37 (44.58%) | 37 (44.58%) | 0.287 |
| TERTp status | |||
| Wild type | 1 (1.20%) | 4 (4.82%) | |
| Mutant | 16 (19.28%) | 16 (19.28%) | 0.348 |
| ATRX status | |||
| Wild type | 72 (86.75%) | 73 (87.95%) | |
| Mutant | 2 (2.41%) | 7 (8.43%) | 0.17 |
| Tumor purity | 0.668 (±0.201) | 0.806 (±0.126) | 2.14E-06 |
| Subtype | |||
| CL | 11 (13.25%) | 40 (48.19%) | |
| ME | 59 (71.08%) | 14 (16.87%) | |
| NE | 3 (3.61%) | 4 (4.82%) | |
| PN | 6 (7.23%) | 13 (15.66%) | 2.81E-11 |